Small-cell lung cancer spreads quickly. From 67%-75% of people who develop small cell lung cancerwill have spread the SCLC outside of the lung to other parts of the body at the time of initial diagnosis. Small-cell lung cancer responds well to chemotherapy (using medications to kill cancer...
Five-year survival rates remain at <10%. However, there has been some progress in the therapy of one histological subtype of lung cancer, small cell lung cancer. Totaling around 20% of lung cancer cases, small cell lung cancer is distinct from the other histologic subtypes in its biologic ...
Navigating treatment combinations in small-cell lung cancer The ETER701 trial demonstrates that a four-drug regimen, involving the addition of anti-angiogenesis therapy to immuno-chemotherapy, improves survival outcomes for extensive-stage small-cell lung cancer — but is more indeed better when it co...
Small cell lung cancer is characterized by early metastases and rapid growth. While initially very responsive to both chemotherapy and radiation therapy, the majority of patients will have recurrent disease or become refractory to treatment. The 5-year survival of patients with small cell lung...
Brit. J. Cancer, 72, 1278-1282 (1995).Grosclaude P, Galat JP, Mace-Lesech J, Roumagnac- Machelard M, Mercier M, Robillard J. Differences in treatment and survival rates of non-small-cell lung can- cer in three regions of France. Br J Cancer 1995;72:1278- 82....
cancer growth and survival. Indeed, cancer can be managed by blocking the target genes related to tumor cell progression without causing noticeable damage to normal cells. Currently, efforts have been focused on improving the targeted therapy aspects regarding the encouraging outcomes in cancer ...
Consolidation durvalumab improved survival across subgroups of patients with limited-stage small cell lung cancer based on factors associated with prior prophylactic cranial irradiation and concurrent chemoradiotherapy use. Among patients with prior PCI in the durvalumab and placebo arms, the median...
This cohort study evaluates trends in survival after immune checkpoint inhibitor therapy in patients with advanced non–small cell lung cancer by age.
Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) J Clin Oncol, 39 (2021), pp. 619-630 CrossrefView in ScopusGoogle Scholar 25 L. Paz-Ares, M. Dvorkin, Y. Chen, ...
cell lung cancer (ES-SCLC) at the time of diagnosis.3SCLC usually shows high sensitivity to initial chemotherapy and radiotherapy. For several decades, the standard of care for patients with ES-SCLC were chemotherapy regimens based on platinum drug combinations and have shown survival benefit. ...